Wall Street Zen upgraded shares of Theravance Biopharma (NASDAQ:TBPH - Free Report) from a hold rating to a buy rating in a research note released on Saturday morning.
Several other brokerages have also weighed in on TBPH. HC Wainwright reiterated a "buy" rating and set a $15.00 price objective on shares of Theravance Biopharma in a report on Tuesday, February 25th. Jones Trading raised shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price target on the stock in a research note on Tuesday, June 17th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $14.50.
Read Our Latest Stock Report on TBPH
Theravance Biopharma Stock Up 0.9%
Shares of TBPH traded up $0.10 on Friday, hitting $10.67. 146,181 shares of the stock traded hands, compared to its average volume of 271,460. Theravance Biopharma has a 1 year low of $7.44 and a 1 year high of $11.82. The stock's 50 day moving average is $9.82 and its two-hundred day moving average is $9.48. The firm has a market capitalization of $533.50 million, a P/E ratio of -9.04 and a beta of -0.09.
Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The business had revenue of $15.39 million for the quarter, compared to analyst estimates of $28.08 million. Theravance Biopharma had a negative return on equity of 32.37% and a negative net margin of 89.38%. Research analysts forecast that Theravance Biopharma will post -1.09 EPS for the current year.
Insider Buying and Selling
In other Theravance Biopharma news, SVP Rhonda Farnum sold 24,000 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $11.00, for a total transaction of $264,000.00. Following the completion of the sale, the senior vice president now directly owns 336,918 shares in the company, valued at $3,706,098. The trade was a 6.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 6.90% of the company's stock.
Institutional Trading of Theravance Biopharma
A number of institutional investors have recently added to or reduced their stakes in TBPH. Nuveen LLC acquired a new position in shares of Theravance Biopharma during the first quarter worth about $3,348,000. Newtyn Management LLC lifted its position in Theravance Biopharma by 5.7% during the 4th quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock worth $44,767,000 after acquiring an additional 258,337 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Theravance Biopharma by 121,993.7% in the 1st quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock worth $1,554,000 after acquiring an additional 174,451 shares during the period. Dimensional Fund Advisors LP grew its position in Theravance Biopharma by 20.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock valued at $5,211,000 after acquiring an additional 95,304 shares in the last quarter. Finally, Jane Street Group LLC raised its stake in shares of Theravance Biopharma by 169.2% during the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock valued at $1,258,000 after purchasing an additional 88,540 shares during the period. 99.10% of the stock is owned by hedge funds and other institutional investors.
About Theravance Biopharma
(
Get Free Report)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
Featured Articles

Before you consider Theravance Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.
While Theravance Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.